November 29, 2016 - By Marguerite Chambers
Equities researchers at Aegis Capital began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a analysts note revealed to clients and investors on 29 November. The firm set a “Buy” rating on the stock. Aegis Capital’s price target of $28.00 suggests potential of 60.46% from the stock’s last stock close.
Out of 4 analysts covering Revance Therapeutics (NASDAQ:RVNC), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. $46 is the highest target while $22 is the lowest. The $34 average target is 92.31% above today’s ($17.68) stock price. Revance Therapeutics has been the topic of 5 analyst reports since August 22, 2015 according to StockzIntelligence Inc. The rating was downgraded by Brean Capital to “Hold” on Tuesday, June 14. The rating was initiated by Guggenheim with “Buy” on Monday, November 23. The firm has “Buy” rating given on Wednesday, March 23 by SunTrust. As per Tuesday, June 14, the company rating was maintained by Suntrust Robinson. The firm earned “Hold” rating on Saturday, August 22 by Zacks.
About 127,316 shares traded hands. Revance Therapeutics Inc (NASDAQ:RVNC) has declined 10.61% since April 26, 2016 and is downtrending. It has underperformed by 15.87% the S&P500.
Analysts await Revance Therapeutics Inc (NASDAQ:RVNC) to report earnings on March, 1. They expect $-0.88 earnings per share, down 6.02% or $0.05 from last year’s $-0.83 per share. After $-0.64 actual earnings per share reported by Revance Therapeutics Inc for the previous quarter, Wall Street now forecasts 37.50% negative EPS growth.
Insitutional Activity: The institutional sentiment decreased to 0.89 in 2016 Q2. Its down 0.50, from 1.39 in 2016Q1. The ratio fall, as 15 funds sold all Revance Therapeutics Inc shares owned while 16 reduced positions. 9 funds bought stakes while 34 increased positions. They now own 28.60 million shares or 5.50% more from 27.11 million shares in 2016Q1.
Wellington Management Gp Llp reported 2.34 million shares or 0.01% of all its holdings. Blackrock Invest Ltd Liability Corporation reported 78,313 shares or 0% of all its holdings. Retail Bank Of Mellon Corporation reported 2.12 million shares or 0.01% of all its holdings. The Massachusetts-based State Street has invested 0% in Revance Therapeutics Inc (NASDAQ:RVNC). Great Point Ptnrs Ltd Liability Corporation holds 0.08% of its portfolio in Revance Therapeutics Inc (NASDAQ:RVNC) for 21,665 shares. Nottingham Inc owns 16,312 shares or 0.04% of their US portfolio. Moreover, Proshare Advsrs Lc has 0% invested in Revance Therapeutics Inc (NASDAQ:RVNC) for 23,688 shares. Finemark Financial Bank Tru accumulated 1,000 shares or 0% of the stock. Canada Pension Plan Invest Board reported 610,300 shares or 0.03% of all its holdings. American Int Gru Inc has 0% invested in the company for 11,769 shares. State Common Retirement Fund holds 0% of its portfolio in Revance Therapeutics Inc (NASDAQ:RVNC) for 18,900 shares. Tudor Investment Et Al, a Connecticut-based fund reported 27,200 shares. Jacobs Levy Equity Mngmt has 51,400 shares for 0.01% of their US portfolio. Barclays Public Limited Com accumulated 3,440 shares or 0% of the stock. Essex Woodlands Ventures owns 4.59 million shares or 15.74% of their US portfolio.
Insider Transactions: Since June 13, 2016, the stock had 0 insider buys, and 3 sales for $411,454 net activity. Shares for $18,250 were sold by Ruegg Curtis. Another trade for 12,000 shares valued at $215,005 was sold by Browne L Daniel.
Revance Therapeutics, Inc. is a biotechnology company. The company has a market cap of $487.92 million. The Firm is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. It currently has negative earnings. The Company’s TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel , or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.
According to Zacks Investment Research, “Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based upon a proprietary TransMTSÂ® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance’s initial focus is on developing daxibotulinumtoxinA, the company’s highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.”
Revance Therapeutics, Inc., incorporated on August 10, 1999, is a biotechnology company. The Firm is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. The Company’s TransMTS technology enables delivery of botulinum toxin type A through approximately two investigational drug product candidates, DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. The Company’s botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. First, its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Second, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials.
Another recent and important Revance Therapeutics Inc (NASDAQ:RVNC) news was published by Fool.com which published an article titled: “Why Revance Therapeutics Is Crashing 23% Today” on June 14, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.